Document:

EX-10.1

 EXHIBIT 10.1 

 

															
		 		  		    		  		  		  		    	
	AWARD/CONTRACT	 		  	 1 THIS CONTRACT IS A RATED ORDER UNDER
  DPAS (15 CFR 700)
	  	RATING	  	 PAGE OF PAGES      

1      |      12      

	 2. CONTRACT (Proc. Inst. Indent.) NO.
 W911QY-12-C-0117
	 		  	 3. EFFECTIVE DATE
  23 Aug 2010
	  	 4. REQUISITION/PURCHASE REQUEST/PROJECT NO.
 W56QTY2199N009

							
	5. ISSUED BY	 	CODE	  	W911QY	    	6. ADMINISTERED BY (If other than Item 5)	  		  	CODE	    	S4801A
						
	   ACC-APG NATICK DIVISION
   1564 FREEDMAN DRIVE
   FORT DETRICK MD 21702
	  		    	    DMCA
    DCMA SEATTLE
    188 106TH AVE, NE SUITE 660

   BELLEVUE WA 98004-8019
	  		  		    	

  

									
	7. NAME AND ADDRESS OF CONTRACTOR (No., street, county, state and zip code)	 	8. DELIVERY	  		  	
					
	    SAREPTA THERAPEUTICS INC	  		 	 ̈  FOB ORIGIN	  	x  OTHER (See below)	  	
	    3450 MONTE VILLA PARKWAY	  		 		  		  	
	    BOTHELL WA 98021	  		 	9. DISCOUNT FOR PROMPT PAYMENT	  	
		  		 	 Net 30 Days	  		  	
		  		 	10. SUBMIT INVOICES	  	ITEM 
	CODE
49WU1                                        
                        FACILITY CODE	 	 (4 copies unless otherwise specified) TO
 THE ADDRESS SHOWN IN:
	  	

  

									
	11. SHIP TO/MARK FOR	  	 CODE W56QTY	  	    12. PAYMENT WILL BE MADE BY	 	CODE	  	HQ0339
			
	 JPM-TMT
 10109 Gridley Road,
bldg 314, 2ND FLOOR
 FT. BELVOIR VA 22060-5865
	  		  	       DFAS-COLUMBUS CETER WESTERN ENTITLEMENT

      PO BOX 182381

      COLUMBUS OH 43218-2381

				
	13, AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION:	  	    14. ACCOUNTING AND APPROPRIATION DATA	 		  	
				
	 [      ] 10 U.S.C.
2304(c) (      )     [      ] 41 U.S.C. 253(c) (      )
	  	    See Schedule	 		  	

  

													
	
15A. ITEM NO.        
	  	 15B, SUPPLIES/SERVICES
	  	
    15C. QUANTITY    
	  	   15D. UNIT  
	  	
  15E. UNIT PRICE  
	  	 15F. AMOUNT 	 
		  	    SEE SCHEDULE	  		  		  		  			
		  		  		  		  		  			
		  		  		  		  		  			
		  		  		  		  		  	  
	  
	 
		  		  	15G. TOTAL AMOUNT OF CONTRACT	  	$	3,878,784.000	  
		  		  		  		  		  	  
	  
	 

 16. TABLE OF CONTENTS 
  

															
	 (X)
	  	 SEC.
	  	 DESCRIPTION
	  	  PAGE(S) 
	  	
    (X)    
	  	SEC.	  	 DESCRIPTION
	  	 PAGE(S)

		  		  	PART I - THE SCHEDULE	  		  		  		  	PART II - CONTRACT CLAUSES	  	
	X	  	A	  	SOLICITATION/CONTRACT FORM	  	1	  	X	  	I	  	CONTRACT CLAUSES	  	6-11
	X	  	B	  	SUPPLIES OR SERVICES AND PRICES/COSTS	  	2	  		  	PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACH.
		  	C	  	DESCRIPTION/SPECS./WORK STATEMENT	  		  	X	  	J	  	LIST OF ATTACHMENTS	  	12
		  	D	  	PACKAGING AND MARKING	  		  		  	PART IV - REPRESENTATIONS AND INSTRUCTIONS
	X	  	E	  	INSPECTION AND ACCEPTANCE	  	3	  		  	K	  	REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS	  	
	X	  	F	  	DELIVERIES OR PERFORMANCE	  	4	  		  	  	  	
	X	  	G	  	CONTRACT ADMINISTRATION DATA	  	5	  		  	L	  	INSTRS., CONDS., AND NOTICES TO OFFERORS	  	
		  	H	  	SPECIAL CONTRACT REQUIREMENTS	  		  		  	M	  	EVALUATION FACTORS FOR AWARD	  	

 CONTRACTING OFFICER WILL COMPLETE ITEM 17 OR 18 AS APPLICABLE 

 

 17.  x   CONTRACTOR’S
NEGOTIATED AGREEMENT Contractor is required to sign this document and return 1 copies to issuing office.) Contractor agrees to furnish and deliver all items or perform all the services set forth or otherwise identified above and on any
continuation sheets for the consideration stated herein. The rights and obligations of the parties to this contract shall be subject to and governed by the following documents: (a) this award/contract, (b) the solicitation, if any, and
(c) such provisions, representations, certifications, and specifications, as are attached or incorporated by_reference herein. (Attachments are listed herein.) 
 19A. NAME AND TITLE OF SIGNER (Type or Print) 
 Chris Garabedian

  

			
	19A. NAME OF CONTRACTOR	  	19C. DATE SIGNED

 

 18.   ̈   AWARD (Contractor is
not required to sign this document.) Your offer on Solicitation Number
                                         
   , including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the terms listed above and on any continuation sheets. This award consummates the contract which
consists of the following documents: (a) the Government’s solicitation and your offer, and (b) this award/contract. No further contractual document is necessary. 
 20A. NAME OF CONTRACTING OFFICER 
 Sandra J. O’Connell 

TEL: [†††] 
 EMAIL:
[†††] 
  

			
	20B. UNITED STATES OF AMERICA	  	20 DATE SIGNED

 
 

  

													
	BY:	 	 /s/ Chris Garabedian
	  		 		  	BY:	  	 /s/ Sandra J. O’Connell
	  	
		 	(Signature of person authorized to sign)	  	08/28/2012	 	        	  		  	(Signature of Contracting Officer)	  	29 Aug 12

  

			
	 AUTHORIZED FOR LOCAL REPRODUCTION
 Previous edition is usable
	  	 STANDARD FORM 26 (REV. 4/2008)

Prescribed by GSA — FAR (48 CFR) 53.214(a)

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 1

 W911QY-12-C-0117 
  Page
 2
 of 12 
  

 Section B - Supplies or Services and Prices 

 

															
	ITEM NO	  	SUPPLIES/SERVICES	  	QUANTITY	  	UNIT	  	UNIT PRICE	 	  	AMOUNT	 
	 0001
	  		  		  		  				  	$	3,878,784.00	  
		  	 IM Formulation Feasiblity Study
	  		  		  				  			
		  	 CPFF
	  		  		  				  			
		  	In accordance with the Contractor’s Statement of Work attached in Section J, to include all Contract Data Requirements List (CDRL) shown as exhibits.	  	  			
		  	 FOB: Destination
	  		  		  				  			
		  	   PURCHASE REQUEST NUMBER: W56QTY2199N009
	  		  		  				  			
		  		  		  		  	 	ESTIMATED COST	 	  	 	$[†††]	  
		  		  		  		  	 	FIXED FEE	 	  	 	$[†††]	  
		  		  		  		  				  	  
	  
	 
		  		  		  		  	 	TOTAL EST COST + FEE	 	  	$	3,878,784.00	  
		  		  		  		  				  	$	3,878,784.00	  
		  	 ACRN AA
	  		  		  				  			
		  	 CIN: W56QTY2199N0090001
	  		  		  				  			

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 2

 W911QY-12-C-0117 
  Page
 3
 of 12 
  

 Section E - Inspection and Acceptance 
 INSPECTION AND ACCEPTANCE TERMS 
 Supplies/services will be inspected/accepted at: 

 

									
	 CLIN
	 	 INSPECT AT
	 	 INSPECT BY
	 	 ACCEPT AT
	 	 ACCEPT BY

	 0001
	 	Destination	 	Government	 	Destination	 	Government

 CLAUSES INCORPORATED BY REFERENCE 
  

					
	 52.246-9
	  	Inspection Of Research And Development (Short Form)	  	APR 1984

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 3

 W911QY-12-C-0117 
  Page
 4
 of 12 
  

 Section F - Deliveries or Performance 
 DELIVERY INFORMATION 
  

													
	 CLIN
	  	 DELIVERY DATE
	  	QUANTITY	 	  	 SHIP TO ADDRESS
	  	UIC	 
	0001	  	 POP 23-AUG-2012 TO
 22-AUG-2013
	  	 	N/A	  	  	 JPM-TMT
 .

10109 GRIDLEY ROAD, BLDG 314, 2ND FLOOR
 FT.
BELVOIR VA 22060-5865
 703-767-1861

FOB: Destination
	  	 	W56QTY	  

 CLAUSES INCORPORATED BY REFERENCE 
  

					
	52.242-15 Alt I	  	Stop-Work Order (Aug 1989) - Alternate I	  	APR 1984
	52.247-34	  	F.O.B. Destination	  	NOV 1991

  
 4 

 W911QY-12-C-0117 
  Page
 5
 of 12 
  

 Section G - Contract Administration Data 
 CONTRACT POINTS OF CONTACT 
 Government Points of Contact: 

Contracting Officer: 
 Sandra J. O’Connell

 [†††] 
 Contracting
Officer’s Representative (COR): 
 Ade Famodu 
 [†††]
 ACCOUNTING AND APPROPRIATION DATA 

AA: 9720400260125Y5YTT40603884BP0255Y12YY44W56QTY2199N009YT4412044008 
 AMOUNT: $3,878,784.00 
 CIN W56QTY2199N0090001: $3,878,784.00 

CLAUSES INCORPORATED BY REFERENCE 

252.204-0001 Line Item Specific: Single Funding
                    SEP 2009 
 KEY
PERSONNEL 
 Key Personnel 

Contractor personnel identified herein are considered “Key” and will only be replaced with 30 day prior notice and concurrence by the
Government: 
 [†††] 

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 5

 W911QY-12-C-0117 
  Page
 6
 of 12 
  

 Section I - Contract Clauses 
 CLAUSES INCORPORATED BY REFERENCE 
  

					
	52.202-1	  	Definitions	  	JAN 2012
	52.203-3	  	Gratuities	  	APR 1984
	52.203-5	  	Covenant Against Contingent Fees	  	APR 1984
	52.203-6	  	Restrictions On Subcontractor Sales To The Government	  	SEP 2006
	52.203-7	  	Anti-Kickback Procedures	  	OCT 2010
	52.203-8	  	Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity	  	JAN 1997
	52.203-10	  	Price Or Fee Adjustment For Illegal Or Improper Activity	  	JAN 1997
	52.203-12	  	Limitation On Payments To Influence Certain Federal Transactions	  	OCT 2010
	52.204-4	  	Printed or Copied Double-Sided on Postconsumer Fiber Content Paper	  	MAY 2011
	52.204-7	  	Central Contractor Registration	  	FEB 2012
	52.204-10	  	Reporting Executive Compensation and First-Tier Subcontract Awards	  	FEB 2012
	52.209-6	  	Protecting the Government’s Interest When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment	  	DEC 2010
	52.209-10	  	Prohibition on Contracting With Inverted Domestic Corporations	  	MAY 2012
	52.215-2	  	Audit and Records—Negotiation	  	OCT 2010
	52.215-8	  	Order of Precedence—Uniform Contract Format	  	OCT 1997
	52.215-11	  	Price Reduction for Defective Certified Cost or Pricing Data—Modifications	  	AUG 2011
	52.215-13	  	Subcontractor Certified Cost or Pricing Data—Modifications	  	OCT 2010
	52.215-15	  	Pension Adjustments and Asset Reversions	  	OCT’ 2010
	52.215-17	  	Waiver of Facilities Capital Cost of Money	  	OCT 1997
	52.215-18	  	Reversion or Adjustment of Plans for Postretirement Benefits (PRB) Other than Pensions	  	JUL 2005
	52.215-19	  	Notification of Ownership Changes	  	OCT 1997
	52.215-21	  	Requirements for Certified Cost or Pricing Data or Information Other Than Certified Cost or Pricing Data—Modifications	  	OCT 2010
	52.215-23 Alt I	  	Limitations on Pass-Through Charges	  	OCT 2009
	52.216-7	  	Allowable Cost And Payment	  	JUN 2011
	52.216-8	  	Fixed Fee	  	JUN 2011
	52.219-8	  	Utilization of Small Business Concerns	  	JAN 2011
	52.219-28	  	Post-Award Small Business Program Rerepresentation	  	APR 2012
	52.222-2	  	Payment For Overtime Premiums	  	JUL 1990
	52.222-3	  	Convict Labor	  	JUN 2003
	52.222-21	  	Prohibition Of Segregated Facilities	  	FEB 1999
	52.222-26	  	Equal Opportunity	  	MAR 2007
	52.222-35	  	Equal Opportunity for Veterans	  	SEP 2010
	52.222-36	  	Affirmative Action For Workers With Disabilities	  	OCT 2010
	52.222-37	  	Employment Reports on Veterans	  	SEP 2010
	52.222-50	  	Combating Trafficking in Persons	  	FEB 2009
	52.222-54	  	Employment Eligibility Verification	  	JAN 2009
	52.223-18	  	Encouraging Contractor Policies To Ban Text Messaging While Driving	  	AUG 2011

  
 6 

 W911QY-12-C-0117 
  Page
 7
 of 12 
  

					
	52.225-13	  	Restrictions on Certain Foreign Purchases	  	JUN 2008
	52.227-1	  	Authorization and Consent	  	DEC 2007
	52.227-1 Alt I	  	Authorization And Consent (Dec 2007) - Alternate I	  	APR 1984
	52.227-2	  	Notice And Assistance Regarding Patent And Copyright Infringement	  	DEC 2007
	52.227-11	  	Patent Rights—Ownership By The Contractor	  	DEC 2007
	52.228-7	  	Insurance—Liability To Third Persons	  	MAR 1996
	52.232-9	  	Limitation On Withholding Of Payments	  	APR 1984
	52.232-23 Alt I	  	Assignment of Claims (Jan 1986) - Alternate I	  	APR 1984
	52.232-25	  	Prompt Payment	  	OCT 2008
	52.232-25 Alt I	  	Prompt Payment (Oct 2008) Alternate I	  	FEB 2002
	52.232-33	  	Payment by Electronic Funds Transfer—Central Contractor Registration	  	OCT 2003
	52.233-1	  	Disputes	  	JUL 2002
	52.233-3 Alt I	  	Protest After Award (Aug 1996) - Alternate I	  	JUN 1985
	52.233-4	  	Applicable Law for Breach of Contract Claim	  	OCT 2004
	52.237-3	  	Continuity Of Services	  	JAN 1991
	52.242-1	  	Notice of Intent to Disallow Costs	  	APR 1984
	52.242-3	  	Penalties for Unallowable Costs	  	MAY 2001
	52.242-4	  	Certification of Final Indirect Costs	  	JAN 1997
	52.242-13	  	Bankruptcy	  	JUL 1995
	52.243-2 Alt V	  	Changes—Cost-Reimbursement (Aug 1987) - Alternate V	  	APR 1984
	52.244-2 Alt I	  	Subcontracts (Oct 2010) - Alternate I	  	JUN 2007
	52.244-5	  	Competition In Subcontracting	  	DEC 1996
	52.244-6	  	Subcontracts for Commercial Items	  	DEC 2010
	52.245-9	  	Use And Charges	  	APR 2012
	52.249-6	  	Termination (Cost Reimbursement)	  	MAY 2004
	52.249-14	  	Excusable Delays	  	APR 1984
	52.253-1	  	Computer Generated Forms	  	JAN 1991
	252.203-7000	  	Requirements Relating to Compensation of Former DoD Officials	  	SEP 2011
	252.203-7001	  	Prohibition On Persons Convicted of Fraud or Other Defense Contract-Related Felonies	  	DEC 2008
	252.203-7002	  	Requirement to Inform Employees of Whistleblower Rights	  	JAN 2009
	252.204-7003	  	Control Of Government Personnel Work Product	  	APR 1992
	252.204-7004 Alt A	  	Central Contractor Registration Alternate A	  	SEP 2007
	252.204-7006	  	Billing Instructions	  	OCT 2005
	252.204-7008	  	Export-Controlled Items	  	APR 2010
	252.205-7000	  	Provision Of Information To Cooperative Agreement Holders	  	DEC 1991
	252.209-7004	  	Subcontracting With Firms That Are Owned or Controlled By The Government of a Terrorist Country	  	DEC 2006
	252.215-7000	  	Pricing Adjustments	  	DEC 1991
	252.225-7012	  	Preference For Certain Domestic Commodities	  	JUN 2012
	252.226-7001	  	Utilization of Indian Organizations and Indian-Owned Economic Enterprises, and Native Hawaiian Small Business Concerns	  	SEP 2004
	252.227-7013	  	Rights in Technical Data—Noncommercial Items	  	FEB 2012
	252.227-7016	  	Rights in Bid or Proposal Information	  	JAN 2011
	252.227-7030	  	Technical Data—Withholding Of Payment	  	MAR 2000
	252.227-7037	  	Validation of Restrictive Markings on Technical Data	  	JUN 2012
	252.227-7039	  	Patents—Reporting Of Subject Inventions	  	APR 1990
	252.231-7000	  	Supplemental Cost Principles	  	DEC 1991
	252.232-7003	  	Electronic Submission of Payment Requests and Receiving Reports	  	JUN 2012

  
 7 

 W911QY-12-C-0117 
  Page
 8
 of 12 
  

					
	252.232-7010	  	Levies on Contract Payments	  	DEC 2006
	252.235-7002	  	Animal Welfare	  	DEC 2011
	252.235-7010	  	Acknowledgment of Support and Disclaimer	  	MAY 1995
	252.235-7011	  	Final Scientific or Technical Report	  	NOV 2004
	252.242-7006	  	Accounting System Administration	  	FEB 2012
	252.243-7002	  	Requests for Equitable Adjustment	  	MAR 1998
	252.244-7000	  	Subcontracts for Commercial Items and Commercial Components (DOD Contracts)	  	JUN 2012
	252.247-7023	  	Transportation of Supplies by Sea	  	MAY 2002
	252.247-7024	  	Notification Of Transportation Of Supplies By Sea	  	MAR 2000

 CLAUSES INCORPORATED BY FULL TEXT 
 52.232-20             LIMITATION OF COST (APR 1984) 
 (a) The parties estimate that performance of this contract, exclusive of any fee, will not cost the Government more than (1) the estimated cost specified in the Schedule or, (2) if this is a
cost-sharing contract, the Government’s share of the estimated cost specified in the Schedule. The Contractor agrees to use its best efforts to perform the work specified in the Schedule and all obligations under this contract within the
estimated cost, which, if this is a cost-sharing contract, includes both the Government’s and the Contractor’s share of the cost. 

(b) The Contractor shall notify the Contracting Officer in writing whenever it has reason to believe that— 

(1) The costs the Contractor expects to incur under this contract in the next 60 days, when added to all costs previously incurred, will exceed 75
percent of the estimated cost specified in the Schedule; or 
 (2) The total cost for the performance of this contract, exclusive of any fee,
will be either greater or substantially less than had been previously estimated. 
 (c) As part of the notification, the Contractor shall
provide the Contracting Officer a revised estimate of the total cost of performing this contract. 
 (d) Except as required by other provisions
of this contract, specifically citing and stated to be an exception to this clause— 
 (1) The Government is not obligated to reimburse the
Contractor for costs incurred in excess of (i) the estimated cost specified in the Schedule or, (ii) if this is a cost-sharing contract, the estimated cost to the Government specified in the Schedule; and 

(2) The Contractor is not obligated to continue performance under this contract (including actions under the Termination clause of this contract) or
otherwise incur costs in excess of the estimated cost specified in the Schedule, until the Contracting Officer (i) notifies the Contractor in writing that the estimated cost has been increased and (ii) provides a revised estimated total
cost of performing this contract. If this is a cost-sharing contract, the increase shall be allocated in accordance with the formula specified in the Schedule. 
 (e) No notice, communication, or representation in any form other than that specified in subparagraph (d)(2) above, or from any person other than the Contracting Officer, shall affect this contract’s
estimated cost to the Government. In the absence of the specified notice, the Government is not obligated to reimburse the Contractor for any costs in excess of the estimated cost or, if this is a cost-sharing contract, for any costs in excess of
the estimated cost to the Government specified in the Schedule, whether those excess costs were incurred during the course of the contract or as a result of termination. 

  
 8 

 W911QY-12-C-0117 
  Page
 9
 of 12 
  

 (f) If the estimated cost specified in the Schedule is increased, any costs the Contractor incurs before
the increase that are in excess of the previously estimated cost shall be allowable to the same extent as if incurred afterward, unless the Contracting Officer issues a termination or other notice directing that the increase is solely to cover
termination or other specified expenses. 
 (g) Change orders shall not be considered an authorization to exceed the estimated cost to the
Government specified in the Schedule, unless they contain a statement increasing the estimated cost. 
 (h) If this contract is terminated or
the estimated cost is not increased, the Government and the Contractor shall negotiate an equitable distribution of all property produced or purchased under the contract, based upon the share of costs incurred by each. 

(End of clause) 
 52.252-2
            CLAUSES INCORPORATED BY REFERENCE (FEB 1998) 
 This contract
incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed
electronically at this/these address(es): 
  

			
	  
	 	
	  
	 	
	  
	 	
	[Insert one or more Internet addresses]	 	
		
	(End of clause)	 	

 252.204-7000     DISCLOSURE OF INFORMATION (DEC 1991) 

(a) The Contractor shall not release to anyone outside the Contractor’s organization any unclassified information, regardless of medium (e.g., film,
tape, document), pertaining to any part of this contract or any program related to this contract, unless— 
 (1) The Contracting Officer
has given prior written approval; or 
 (2) The information is otherwise in the public domain before the date of release. 

(b) Requests for approval shall identify the specific information to be released, the medium to be used, and the purpose for the release. The Contractor
shall submit its request to the Contracting Officer at least 45 days before the proposed date for release. 
 (c) The Contractor agrees to
include a similar requirement in each subcontract under this contract. Subcontractors shall submit requests for authorization to release through the prime contractor to the Contracting Officer. 

(End of clause) 
 ACCOUNTING FOR CONTRACT
SERVICES REQUIREMENT (Sep 2011) 
 ACC-APG 5152.237-4005

  
 9 

 W911QY-12-C-0117 
  Page
 10
 of 12 
  

 The Office of the Assistant Secretary of the Army (Manpower & Reserve Affairs)
operates and maintains a secure Army data collection site where the contractor shall report ALL contractor manpower (including subcontractor manpower) required for performance of this contract. The Army’s objective is to collect as much
significant Contractor Man-Year Equivalents (CME) data as possible to allow accurate reporting to Congress and for effective Army planning. Detailed instructions can be found on the Contractor Manpower Reporting Application (CMRA) website in the
CMRA “Contractor User Guide” or “Subcontractor User Guide”. The contractor must create an account upon entering the site and is required to completely fill in the required information at the CMRA website:
https://cmra.army.mil. 
 The required information includes: 

 

	 	(1)	Unit Identification Code (UIC) of the Army Requiring Activity that would be performing the mission if not for the contractor: W56QTY. 

	 	(2)	Command of the Requiring Activity that would be performing the mission if not for the contractor: JPEO. 

	 	(3)	Contracting Officer (KO) and contact information:              Sandra J. O’Connell,
[†††], [†††]). 

	 	(4)	Contracting Officer’s Representative (COR) and contact information:              Ade Famodu,
[†††], [†††]. 

	 	(5)	Federal Service Code (FSC) reflecting services provided by contractor (and separate FSC for each subcontractor if different). If there are multiple FSCs for an Order
number, enter a separate data record for each FSC. 

	 	(6)	Location where contractor and subcontractor(s) perform the service, including the city, state, zip code, and country. When service is performed at an overseas location,
state only the city and country. If there are multiple Locations for an Order number, enter a separate data record for each Location. (Note: If there are many location records that need to be entered, the Bulk Loader function is available which
allows the transfer of information from a contractor’s system to the secure web site. The Bulk Loader Template and Bulk Loader Instructions may be downloaded from the web site.) 

	 	(7)	Contractor Type (prime or subcontractor). 

	 	(8)	Direct labor hours (including subcontractors) for each FSC. 

	 	(9)	Direct labor dollars paid this reporting period (including subcontractors) for each FSC. 

	 	(10)	Weapons system support indication:              No   (Enter yes or no).

 If subcontractors are used in the performance of this contract, several factors must be considered. Contractor
shall include, and require inclusion of, this term in all subcontracts at any tier under the contract in which services are being procured. Contractor shall also enter their data in a timely manner, as subcontractors can not input any information
into the CMRA system until the Prime Contractor has entered their data. The Prime Contractor has overall responsibility for ensuring subcontractors enter their respective data. Subcontractors are only responsible for entering Location Data.

 Reporting period will be the period of performance not to exceed 12 months ending 30 September of each government fiscal
year and must be reported by 31 October of each calendar year. 
 5152.232-7003     INVOKING INSTRUCTIONS AND
PAYMENT (WAWF INSTRUCTIONS) (NCD) (AUG 2009) 
 (a) Invoices for goods received or services rendered under this contract
shall be submitted electronically through Wide Area Work Flow - Receipt and Acceptance (WAWF): 
 (1) The vendor shall
self-register at the web site https://wawf.eb.mil. Vendor training is available on the Internet at http://www.wawftraining.com. 

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 10

 W911QY-12-C-0117 
  Page
 11
 of 12 
  

 (2) Select the invoice type within WAWF as specified below. Back up documentation (such
as timesheets, etc.) can be included and attached to the invoice in WAWF. Attachments created in any Microsoft Office product are attachable to the invoice in WAWF. Total limit for the size of files per invoice is 5 megabytes. 

(b) The following information, regarding invoice routing DODAAC’s, must be entered for completion of the invoice in WAWF:

  

			
	Cost Voucher (T&M - LH - Cost)
	Pay DoDAAC	  	HQ0339
	IssueBy DoDAAC	  	W911QY
	Admin DoDAAC	  	W911QY
	 DCAA Auditor

DoDAAC
	  	HAA035
	Service Approver	  	S4801A
	LPO (For Navy Only)	  	

 (c) The contractor shall submit invoices / cost vouchers for payment per contract terms. 

(d) The Government shall process invoices / cost vouchers for payment per contract terms. 

(e) For each invoice / cost voucher submitted for payment, the contractor shall also email the WAWF automated invoice notice directly to
the following points of contact: 
  

							
	 Name
	 	 Email
	 	 Phone
	 	 Job Title

	Sandra O’Connell	 	[†††]	 	[†††]	 	Contracting Officer
	Ade Famodu	 	[†††]	 	[†††]	 	COR
	Suzzette Kim	 	[†††]	 	[†††]	 	Budget Analyst

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 11

 W911QY-12-C-0117 
  Page
 12
 of 12 
  

 Section J - List of Documents, Exhibits and Other Attachments 

LIST OF ATTACHMENTS 
 List of Attachments

  

	 	1.	Contractor’s Statement of Work, dated 9 Aug 2012 

 List of Exhibits 
 A001 Contract Work Breakdown Structure 

A002 Contractor’s Progress, Status and Management Report 
 A003 Integrated Master Schedule 
 A004 Contract Funds Status Report 

A005 Final Report 

  
 12 

 Statement of Work (SOW) 
 Statement of Objectives and Overall Scope 
 The activities in this proposal
are intended to support evaluation of the initial feasibility of an IM route of administration of Sarepta’s antiviral drug AVI-7288 against marburgvirus. Demonstration of the feasibility of the IM route has the potential to reduce the
logistical burden on the Warfighter relative to the current intravenous (IV) route presently under development by Sarepta as a counter measure to the marburgvirus threat. 
 The scope of work for this contract includes: manufacturing activities; formulation development; an IM [†††] Study; an IM [†††] Feasibility Study using a lethal
challenge marburgvirus model; and quality assurance, management and administrative activities. The plan for accomplishing the program consists of four key steps: 
 Step 1: Manufacture sufficient drug product (AVI-7288) to support Steps 4. 
 Step 2: Develop [†††]-based formulation of AVI-7288. 

Step 3: Assess [†††] of the [†††]-based formulation via the IM route in the
[†††] (the IM [†††] Study). 
 Step 4: Test the efficacy of [†††]-based
formulation via the IM route in the [†††] marburgvirus model [†††] (the IM [†††] Feasibility Study). 
 Requirements 
  

							
	 Paragraph
	  	 Statement of Work

	2.1.2.1	  	Program Management
	2.1.2.1.1	  	Technical/Program Management
	2.1.2.1.1.1	  	Sarepta shall appoint a Program Manager. The Program Manager shall maintain oversight and control of the functional execution of the study. Therefore the Program
Manager shall:

 Oversee resource and personnel deployment so as to
ensure timely execution of program tasks in support of program objectives 
 Oversee the budget and track expenditures in
support of program objectives. 
 Identify and track risks to project execution and compliance; identify and implement risk
mitigation plans and corrective actions plans as required in support of program objectives. 
 Maintain and update the
Integrated Master Schedule as needed to track program progress in support of program objectives. 
  

							
		
	2.1.2.1.1.2	  	Sarepta shall conduct internal and external customer and subcontractor meetings to coordinate the activities of the program. The Program Manager
shall:
				
		  		  	      1)	 	 Conduct internal management and functional group meetings to ensure timely program schedule execution, compliance with budgetary constraints, and
FAR and DFAR compliance in support of program objectives.

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 13

									
	 Paragraph
	  	 Statement of Work

				
		  		  	 	      2)	  	 	 Conduct and/or ensure Sarepta participation in external management meetings with contract service providers to ensure timely program schedule
execution, compliance with budgetary constraints, and relevant and FAR and DFAR compliance in support of program objectives.

				
		  		  	 	      3)	  	 	 Conduct and/or ensure Sarepta participation in external meetings with the customer in support of program objectives.

		
	 2.1.2.1.2
	  	Management Reporting
		
	 2.1.2.1.2.1
	  	Sarepta shall prepare monthly and quarterly technical progress reports, and a final summary report of all appropriate program findings. The reports shall be submitted
to Sarepta Management and the customer. The reports shall describe or provide:
				
		  		  	 	1	) 	 	 Technical progress and Milestone achievements.

				
		  		  	 	2	) 	 	 Schedule progress

				
		  		  	 	3	) 	 	 Future program plans (e.g. site visits).

				
		  		  	 	4	) 	 	 Program Risks and Mitigations Plans when identified.

				
		  		  	 	5	) 	 	 Copies of Draft Study Reports and Final Study Reports when available.

				
		  		  	 	6	) 	 	 Copies of IACUC and ACURO submission and responses/protocol approvals.

				
		  		  	 	7	) 	 	 Copies of FDA communications.

			
		  		  	  
 
	 Decision: Sarepta shall provide a final summation of all appropriate program study results to
USG
[†††].

		
	 2.1.2.1.3
	  	Travel
		
	 2.1.2.1.3.1
	  	Sarepta shall conduct travel in support of this program for the purpose of good communication with the USG and managing/overseeing subcontracted efforts. Site visits
of subcontractors shall include:
				
		  		  	 	1	) 	 	 Reviews of study/task performance.

				
		  		  	 	2	) 	 	 Review of study/task records.

				
		  		  	 	3	) 	 	 Observation of representative study/task related procedures and processes as appropriate.

		
	 2.1.2.2
	  	Chemistry Manufacturing and Controls (CMC)
		
	 2.1.2.2.1
	  	CMC Management
		
	 2.1.2.2.1.1
	  	Sarepta shall provide functional area management staff responsible for managing and controlling CMC activities supporting the program objectives. The CMC management
will:
				
		  		  	 	      1)	  	 	 Oversee resource and personnel deployment so as to ensure timely execution of program tasks in support of program
objectives.

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 14

							
	 Paragraph
	  	 Statement of Work

				
		  		  	      2)	 	Oversee the budget and track expenditures in support of program objectives.
				
		  		  	      3)	 	Identify and track risks to project execution and compliance; identify and implement risk mitigation plans and corrective actions plans as required in support of program
objectives.
		
	2.1.2.2.1.2	  	Sarepta shall conduct internal and external customer and subcontractor meetings to coordinate technical activities of the manufacturing activities performed in
support of program objectives. The CMC management will:
				
		  		  	      1)	 	 Conduct internal management and functional group meetings to ensure timely program schedule execution, compliance with budgetary constraints, and
FAR and DFAR compliance in support of program objectives.

				
		  		  	      2)	 	 Conduct and/or ensure Sarepta Therapeutics participation in external management meetings with contract service providers to ensure timely program
schedule execution, compliance with budgetary constraints, and relevant and FAR and DFAR compliance in support of program objectives.

				
		  		  	      3)	 	 Conduct and/or ensure Sarepta participation in external meetings with the customer in support of program objectives.

		
	2.1.2.2.1.3	  	Sarepta shall conduct periodic on-site monitoring of study performance at subcontractor work sites for the purpose of ensuring proper work performance and progress of
activities performed in support of program objectives. During on-site visits, the CMC management will:
				
		  		  	      1)	 	 Review progress against the program goals and schedule.

				
		  		  	      2)	 	 Discuss issues and risks with the potential impact scope, schedule and/or budget.

				
		  		  	      3)	 	 Reach agreement with the subcontractor on the design of future studies/work.

		
	2.1.2.2.2	  	[†††] Manufacturing
		
	2.1.2.2.2.1	  	Sarepta shall contract for the manufacturing of the Active Pharmaceutical Ingredient (API) AVI-7288 at one or more Contract Manufacturing Organization(s) in
sufficient quantities and quality to support program objectives. This effort will include:
				
		  		  	      1)	 	 Contracting with a suitable CRO for manufacture.

				
		  		  	      2)	 	 Providing necessary [†††].

				
		  		  	      3)	 	 Manufacture of the [†††].

				
		  		  	      4)	 	 Release testing.

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 15

							
	 Paragraph
	  	 Statement of Work

		  		  	      5)	 	 Quality Assurance review of the batch record.

			
		  		  	      Decision: [†††].
		
	2.1.2.2.3	  	Formulation
		
	2.1.2.2.3.1	  	Sarepta shall generate internally, the development of a formulation method of the API, AVI-7288, [†††]
			
		  		  	      Decision: [†††]
		
	2.1.2.2.4	  	Controls
		
	2.1.2.2.4.1	  	Sarepta shall conduct reviews of both in process and study records to determine and document that adequate quality control (QC) practices and QC documentation
requirements were performed throughout the execution of all manufacturing and formulation development activities performed in support of the program objectives. This effort will include:
				
		  		  	      1)	 	 Batch record review of the API manufacture.

				
		  		  	      2)	 	 Review of analytical testing data for both API and the formulation.

			
		  		  	Decision: Acceptance of study records. [†††]
		
	2.1.2.2.4.2	  	Sarepta shall conduct reviews of both in process and study records to determine and document that adequate quality assurance (QA) practices and QA documentation
requirements were performed throughout the execution of all manufacturing and formulation development activities performed in support of the program objectives. This effort will include:
				
		  		  	      1)	 	 Review of the draft batch record.

				
		  		  	      2)	 	 Review of the completed batch record post production.

			
		  		  	      Decision: Acceptance of study records. [†††]
		
	2.1.2.3	  	Nonclinical
		
	2.1.2.3.1	  	Nonclinical Management
		
	2.1.2.3.1.1	  	Sarepta shall provide functional area management staff responsible for managing and controlling nonclinical activities supporting the program objectives. The
Functional Manager shall:
				
		  		  	      1)	 	 Participate in internal management and functional group meetings to ensure timely program schedule execution, compliance with budgetary
constraints, and FAR and DFAR compliance in support of program objectives.

				
		  		  	      2)	 	 Participate in external management meetings with contract service providers to ensure timely program schedule execution, compliance with budgetary
constraints, and relevant and FAR and DFAR compliance as appropriate in support of program objectives.

				
		  		  	      3)	 	 Participate in external meetings with the customer for the purpose of ensuring proper work performance and progress of activities performed in
support of program objectives.

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 16

									
	 Paragraph
	  	 	  	 Statement of Work

		  		  	      4)
	 	Contribute to the preparation of periodic progress reports to USG detailing schedule progress at the task level, schedule and cost variance, schedule and cost risk,
program milestones, and future program plans in support of program objectives.
		
	2.1.2.3.1.2	  	Sarepta shall conduct internal and external customer and subcontractor meetings to coordinate nonclinical technical activities performed in support of the
program objectives.  
 Sarepta shall conduct periodic on-site monitoring of
study performance at subcontractor work sites for the purpose of ensuring proper work performance and progress of activities performed in support of program objectives.

	2.1.2.3.1.3	  
		
	2.1.2.3.2	  	IM [†††] Study
					
	2.1.2.3.2.1	  		  		 	    [†††]	  	
			
		  	.	  	      Decision: Final Report accepted. [†††]
 
       Decision: Final Report
accepted

					
		  		  		 	    [†††]	  	
			
		  	.	  	      Decision: Final Report accepted
					
		  		  	      1)	 	    [†††]	  	
			
		  		  	      Decision: Final Report accepted.
		
	2.1.2.3.3	  	IM [†††] Feasibility Study
					
	2.1.2.3.3.1	  		  		 	    [†††]	  	
			
		  		  	      Decision: In-life phase of study is authorized to proceed.
					
	2.1.2.3.3.2	  		  		 	    [†††]	  	
			
		  		  	      Decision: [†††]  

      Decision: [†††]

 
       Decision: Final Report accepted.
[†††]

					
	2.1.2.3.3.3	  		  		 	    [†††]	  	
			
		  		  	      Decision: Primary and secondary study endpoint data recorded and documented in a manner sufficient to meet study
objectives and included in draft report and final report.
					
		  		  		 	    [†††]	  	
			
		  		  	      Decision: Bioanalysis Final Report accepted. [†††]
					
		  		  		 	    [†††]	  	
			
		  		  	      Decision: Pharmacokinetic Final Report accepted.

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 17

							
	 Paragraph
	  	 Statement of Work

	2.1.2.3.3.4	  		  		 	    [†††]
			
		  		  	      Decision: Final Report accepted. Submit Final Report to customer and FDA.
		
	2.1.2.4	  	Regulatory
		
	2.1.2.4.1	  	Development of ROM Options [†††]
		
	2.1.2.4.1.1	  	Sarepta shall develop a comprehensive ROM [†††]. The ROM shall consider:
				
		  		  	    1)	 	Program Management requirements
				
		  		  	    2)	 	CMC requirements
				
		  		  	    3)	 	Nonclinical requirements
				
		  		  	    4)	 	Regulatory requirements
				
		  		  	    5)	 	Analytical Chemistry and QA requirements
				
		  		  	    6)	 	Quality Control requirements
				
		  		  	    7)	 	Material requirements
				
		  		  	    8)	 	Other program requirements
			
		  		  	    Decision: Acceptance of ROM [†††] by customer.

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 18

																									
	
CONTRACT DATA REQUIREMENTS LIST
 (2 Data Items)
	 	 Form Approved

OMB No. 0704-0188
	 		 	
	The public reporting burden for this collection
of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.
Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware
that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the
above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.	 		 	
	A. CONTRACT LINE ITEM NO.	 	B. EXHIBIT	 		 	C. CATEGORY	 		 		 		 		 		 		 	
	1	 	 	 	A	 	 	 	TDP	 	TM	 	            OTHER	 	N/A	 	 	 	 	 		 	
	D. SYSTEM/ITEM	 		 		 	 	 	E. CONTRACT/PR NO.	 	F. CONTRACTOR	 		 		 		 		 	
	IM Formulation Feasibility Study	 	 	 	W911QY-12-C-0117	 	Sarepta Therapeutics	 		 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		 	
	 1. DATA ITEM NO.

A001
	 	 2. TITLE OF DATA ITEM

Contract Work Break Down Structure
	 	 3. SUBTITLE

N/A
	 		 		 		 		 	 17. PRICE

GROUP

	4. AUTHORITY (Data Acquisition Document No.)	 	5. CONTRACT REFERENCE	 	 	 	6. REQUIRING OFFICE	 		 	 
	DI-MGMT-81334D	 	N/A	 	 	 	JPM/TMT	 		 	18. ESTIMATED
	7. DD 250 REQ	 	9. DIST STATEMENT	 	10. FREQUENCY	 	12. DATE OF FIRST	 	 	 	14.         Distribution	 		 	TOTAL PRICE
	LT	 	    REQUIRED	 	See Blk 16	 	     SUBMISSION	 	 	 		 	b. COPIES	 		 	 
	 	 		 	 	 	 	 	See Blk 16	 	 	 	 	 	 		 	
	8. APP CODE	 	N/A	 	11. AS OF DATE	 	13. DATE OF	 	 	 	a. ADDRESSEE	 	 	 	Final	 		 	
	 	 		 	 	 	 	 	     SUBSEQUENT	 	 	 	 	Draft	 	 		 	
	A	 		 	 	 	See Blk 16	 	     SUBMISSION	 	 	 		 	 	Reg	 	Repro	 		 	
	 	 	 	 	 	 	 	 	See Blk 16	 	 	 	 	 	 	 	 	 	 
	 16. REMARKS

A 4-Level WBS with costs and schedule per each level. For the lowest task level show the breakdown for labor, material and other indirect costs. BLK 10-13
submit [†††] days after contract award. Government will review and approve at kick off meeting.
  
 Submission of the CWBS to the Defense Cost and Resource Center (DCARC) as mentioned in Paragraph 2 of the DID is not required.
	 	JPM TMT/COR	 	 	 	1	 	 	 		 	
	 	PCO	 	 	 	1	 	 	 		 	
	 	ACO	 	 	 	1	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	15. TOTAL®	 	0	 	3	 	0	 		 	
	 1. DATA ITEM NO.

A002
	 	 2. TITLE OF DATA ITEM
 Contractor’s Progress, Status and Management Report
	 	 3. SUBTITLE
 N/A
	 		 	 17. PRICE

GROUP

	4. AUTHORITY (Data Acquisition Document No.)	 	5. CONTRACT REFERENCE	 	 	 	6. REQUIRING OFFICE	 		 	 
	DI-ADMIN-80227	 	N/A	 	 	 	                     
           JPM/TMT	 		 	18. ESTIMATED
	7. DD 250 REQ	 	9. DIST STATEMENT	 	10. FREQUENCY	 	12. DATE OF FIRST	 	 	 	14.         Distribution	 		 	TOTAL PRICE
	LT	 	    REQUIRED	 	See Blk 16	 	      SUBMISSION	 	 	 		 	b. COPIES	 		 	 
	 	 		 	 	 	 	 	See Blk 16	 	 	 	 	 	 		 	
	8. APP CODE	 	N/A	 	11. AS OF DATE	 	13. DATE OF	 	 	 	a. ADDRESSEE	 	 	 	Final	 		 	
	A	 		 	 	 	See Blk 16	 	      SUBSEQUENT	 	 	 	 	Draft	 	 		 	
	 	 		 	 	 	 	 	      SUBMISSION	 	 	 		 	 	Reg	 	Repro	 		 	
	 	 	 	 	 	 	 	 	See Blk 16	 	 	 	 	 	 	 	 	 	 
	 16. REMARKS

Monthly Technical Presentation via Teleconference to be conducted on a schedule to be set at contract kick off.

Quarterly Status Report due within [†††] calendar days of the end of each Government Fiscal Quarter.

Draft and Final reports of the Tolerability study and the Feasibility study. Draft reports are due within 15 calendar days of the completion of the
in-life portion of the studies.
 In- Process Review at the midpoint of contract performance.

All reports are subject to review/approval within [†††] calendar days after receipt of the first submittal. Provide changes to draft
within 10 calendar days
	 	JPM TMT/COR	 	 	 	1	 	 	 		 	
	 	PCO	 	 	 	1	 	 	 		 	
	 	ACO	 	 	 	1	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	15. TOTAL®	 	0	 	3	 	0	 		 	
	G. PREPARED BY	 	H. DATE	 	I. APPROVED BY	 		 		 	J. DATE	 		 	
	 /s/ [Illegible]
	 	8/20/12	 	 	 	 /s/ [Illegible]
	 	 	 	 	 	   8/20/12
	 		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	Page 1 or 3 Pages

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

																									
	
CONTRACT DATA REQUIREMENTS LIST
 (2 Data Items)
	 	 Form Approved

OMB No. 0704-0188
	 		 	
	The public reporting burden for this collection
of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.
Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware
that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the
above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.	 		 	
	A. CONTRACT LINE ITEM NO.	 	B. EXHIBIT	 		 	C. CATEGORY	 		 		 		 		 		 		 	
	1	 	 	 	A	 	 	 	TDP	 	TM            OTHER        
N/A	 	 	 		 	
	D. SYSTEM/ITEM	 		 		 	 	 	E. CONTRACT/PR NO.	 	F. CONTRACTOR	 		 		 		 		 	
	IM Formulation Feasibility Study  	 	 	 	W911QY-12-C-0117	 	Sarepta Therapeutics	 		 	
	 1. DATA ITEM NO.

A003
	 	 2. TITLE OF DATA ITEM

Integrated Master Schedule
	 	 3. SUBTITLE

N/A
	 		 		 		 		 	 17. PRICE

GROUP

	4. AUTHORITY (Data Acquisition Document No.)	 	5. CONTRACT REFERENCE	 	6. REQUIRING OFFICE	 		 	 
	DI-MGMT-81650	 	N/A	 	 	 	JPM/TMT	 		 	18. ESTIMATED
	7. DD 250 REQ	 	9. DIST STATEMENT	 	10. FREQUENCY	 	12. DATE OF FIRST	 	14.         Distribution	 		 	TOTAL PRICE
	LT	 	    REQUIRED	 	      See Blk 16	 	     SUBMISSION	 	 	 		 	b. COPIES	 		 	 
	 	 		 	 	 	 	 	See Blk 16	 	 	 	 	 	 		 	
	8. APP CODE	 	N/A	 	11. AS OF DATE	 	13. DATE OF	 	 	 	a. ADDRESSEE	 	 	 	Final	 		 	
	 	 		 	 	 	      See Blk 16	 	     SUBSEQUENT	 	 	 	 	Draft	 	 		 	
	A	 		 	 	 	 	 	     SUBMISSION	 	 	 		 	 	Reg	 	Repro	 		 	
	 	 	 	 	 	 	 	 	See Blk 16	 	 	 	 	 	 	 	 	 	 
	 16. REMARKS

 
 BLK 10-13 submit [†††] days after contract award. Government will
review and approve at kick off meeting,. IMS will be statused monthly as of the end of the calendar month and reviewed as part of the monthly technical presentation/teleconference.
	 	JPM TMT/COR	 	 	 	1	 	 	 		 	
	 	PCO	 	 	 	1	 	 	 		 	
	 	ACO	 	 	 	1	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	15. TOTAL®	 	0	 	3	 	0	 		 	
	 1. DATA ITEM NO.

A004
	 	 2. TITLE OF DATA ITEM
 Contract Funds Status Report
	 	 3. SUBTITLE

Project Spend Plan
	 		 	 17. PRICE

GROUP

	4. AUTHORITY (Data Acquisition Document No.)	 	5. CONTRACT REFERENCE	 	 	 	6. REQUIRING OFFICE	 		 	 
	DI-MGMT-81468	 	N/A	 	 	 	JPM/TMT	 		 	18. ESTIMATED
	7. DD 250 REQ	 	9. DIST STATEMENT	 	10. FREQUENCY	 	12. DATE OF FIRST	 	14.         Distribution	 		 	TOTAL PRICE
	LT	 	    REQUIRED	 	See Blk 16	 	     SUBMISSION	 	 	 		 	b. COPIES	 		 	 
	 	 		 	 	 	 	 	See Blk 16	 	 	 	 	 	 		 	
	8. APP CODE	 	N/A	 	11. AS OF DATE	 	13. DATE OF	 	 	 	a. ADDRESSEE	 	 	 	Final	 		 	
	A	 		 	 	 	See Blk 16	 	     SUBSEQUENT	 	 	 	 	Draft	 	 		 	
	 	 		 	 	 	 	 	     SUBMISSION	 	 	 		 	 	Reg	 	Repro	 		 	
	 	 	 	 	 	 	 	 	See Blk 16	 	 	 	 	 	 	 	 	 	 
	 16. REMARKS

 
 BLKs 10-13: Contractor will provide an updated expenditure forecast reflecting actual
negotiated costs over entire period of performance within [†††] calendar days. The spend plan should detail the planned expenditure by month. The Government review/approval will occur at the contract kick off.

The Contract Funds Status Report will be statused [†††] within [†††] calendar days of the end of the contractor’s
accounting period.
	 	JPM TMT/COR	 	 	 	1	 	 	 		 	
	 	PCO	 	 	 	1	 	 	 		 	
	 	ACO	 	 	 	1	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	15. TOTAL	 	0	 	3	 	0	 		 	
	G. PREPARED BY	 	H. DATE	 	I. APPROVED BY	 		 		 	J. DATE	 		 	
	 /s/ [Illegible]
	 	8/20/12	 	 	 	 /s/ [Illegible]
	 	 	 	 	 	   8/20/12
	 		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	Page 2 or 3 Pages

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

																									
	
CONTRACT DATA REQUIREMENTS LIST
 (2 Data Items)
	 	 Form Approved

OMB No. 0704-0188
	 		 	
	The public reporting burden for this collection
of information is estimated to average 220 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.
Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Services Directorate (0704-0188). Respondents should be aware
that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Please do not return your form to the
above organization. Send completed form to the Government Issuing Contracting Officer for the Contract/PR No. listed in Block E.	 		 	
	A. CONTRACT LINE ITEM NO.	 	B. EXHIBIT	 		 	C. CATEGORY	 		 		 		 		 		 		 	
	1	 	 	 	A	 	 	 	TDP	 	TM	 	            OTHER	 	N/A	 	 	 	 	 		 	
	D. SYSTEM/ITEM	 		 		 	 	 	E. CONTRACT/PR NO.	 	F. CONTRACTOR	 		 		 		 		 	
	IM Formulation Feasibility Study	 	W911QY-12-C-0117	 	Sarepta Therapeutics	 		 	
	 1. DATA ITEM NO.

A005
	 	 2. TITLE OF DATA ITEM
 Final Report
	 	 3. SUBTITLE

N/A
	 		 		 		 		 	 17. PRICE

GROUP

	4. AUTHORITY (Data Acquisition Document No.)	 	5. CONTRACT REFERENCE	 	 	 	6. REQUIRING OFFICE	 		 	 
	DI-MISC-80508B	 	N/A	 	 	 	JPM/TMT	 		 	18. ESTIMATED
	7. DD 250 REQ	 	9. DIST STATEMENT	 	10. FREQUENCY	 	12. DATE OF FIRST	 	 	 	14.         Distribution	 		 	TOTAL PRICE
	LT	 	    REQUIRED	 	See Blk 16	 	      SUBMISSION	 	 	 		 	b. COPIES	 		 	 
	 	 		 	 	 	 	 	See Blk 16	 	 	 	 	 	 		 	
	8. APP CODE	 	N/A	 	11. AS OF DATE	 	13. DATE OF	 	 	 	a. ADDRESSEE	 	 	 	Final	 		 	
	 	 		 	 	 	 	 	      SUBSEQUENT	 	 	 	 	Draft	 	 		 	
	A	 		 	 	 	 	 	      SUBMISSION	 	 	 		 	 	Reg	 	Repro	 		 	
	 	 	 	 	 	 	See Blk 16	 	See Blk 16	 	 	 	 	 	 	 	 	 	 
	 16. REMARKS

The Final report, if an alternate route of administration is determined to be feasible, will include [†††] that assesses the requirements
at a level 3 work breakdown structure (rough order of magnitude schedule and cost) [†††]
 Contractor Format Acceptable -
Submission is due within [†††] Calendar days of the completion of the IM Feasibility study will be reviewed for completeness by the Government for [†††] Calendar days after the submission and the contractor
will have [†††] Calendar days to resubmit the Final Report after resolution of the Government’s comments.
	 	JPM TMT/COR	 	 	 	1	 	 	 		 	
	 	PCO	 	 	 	1	 	 	 		 	
	 	ACO	 	 	 	1	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	15. TOTAL	 	0	 	3	 	0	 		 	
	 1. DATA ITEM NO.

    
	 	2. TITLE OF DATA ITEM	 	3. SUBTITLE	 		 	 17. PRICE

GROUP

	4. AUTHORITY (Data Acquisition Document No.)	 	5. CONTRACT REFERENCE	 	 	 	6. REQUIRING OFFICE	 		 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 		 	18. ESTIMATED
	7. DD 250 REQ	 	9. DIST STATEMENT	 	10. FREQUENCY	 	12. DATE OF FIRST	 	 	 	14.         Distribution	 		 	TOTAL PRICE
	 	 	    REQUIRED	 	 	 	     SUBMISSION	 	 	 		 	b. COPIES	 		 	 
	 	 		 	 	 	 	 	 	 	 	 	 	 	 		 	
	8. APP CODE	 	 	 	11. AS OF DATE	 	13. DATE OF	 	 	 	a. ADDRESSEE	 	 	 	Final	 		 	
	 	 		 	 	 	 	 	     SUBSEQUENT	 	 	 	 	Draft	 	 		 	
	 	 		 	 	 	 	 	     SUBMISSION	 	 	 		 	 	Reg	 	Repro	 		 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	16. REMARKS	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	 	 	 	 	 	 	 	 		 	
	 	15. TOTAL	 	0	 	0	 	0	 		 	
	G. PREPARED BY	 	H. DATE	 	I. APPROVED BY	 		 		 	J. DATE	 		 	
	 /s/ [ILLEGIBLE]
	 	8/20/12	 	 	 	 /s/ [ILLEGIBLE]
	 	 	 	   8/20/12
	 		 	

					
	DD FORM 1423-2, AUG 96	  	PREVIOUS EDITION MAY BE USED.	  	Page 3 of 3 Pages  

  

	[†††]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

			
	 INSTRUCTIONS FOR
COMPLETING DD FORM 1423
 (See DoD 5010. 12-M for detailed instructions.)

	
FOR GOVERNMENT PERSONNEL
  

Item A. Self-explanatory.
  

Item B. Self-explanatory.
  

Item C. Mark (X) appropriate category: TDP - Technical Data Package; TM - Technical Manual; Other - other category of data, such as
“Provisioning,” “Configuration Management,” etc.
  

Item D. Enter name of system/item being acquired that data will support.

 
 Item E. Self-explanatory (to be filled in after contract
award).
  
 Item F. Self-explanatory (to be filled in after
contract award).
  
 Item G. Signature of preparer of
CDRL.
  
 Item H. Date CDRL was prepared.

 
 Item I. Signature of CDRL approval authority.

 
 Item J. Date CDRL was approved.

 
 Item 1. See DoD FAR Supplement Subpart 4.71 for proper
numbering.
  
 Item 2. Enter title as it appears on data
acquisition document cited in Item 4.
  
 Item 3. Enter
subtitle of data item for further definition of data item (optional entry).
  

Item 4. Enter Data Item Description (DID) number, military specification number, or military standard number listed in DoD 5010.12-L (AMSDL),
or one-time DID number, that defines data content and format requirements.
  

Item 5. Enter reference to tasking in contract that generates requirement for the data item (e.g., Statement of Work paragraph
number).
  
 Item 6. Enter technical office responsible for
ensuring adequacy of the data item.
  
 Item 7. Specify
requirement for inspection/acceptance of the data item by the Government.
  

Item 8. Specify requirement for approval of a draft before preparation of the final data item.

 
 Item 9. For technical data, specify requirement for contractor to mark
the appropriate distribution statement on the data (ref. DoDD 5230.24).
  
 Item 10. Specify number of times data items are to be delivered.
  
 Item 11. Specify as-of date of data item, when applicable.
  
 Item 12. Specify when first submittal is required.
  
 Item 13. Specify when subsequent submittals are required, when applicable.
  

Item 14. Enter addressees and number of draft/final copies to be delivered to each addressee. Explain reproducible copies in
Item 16.
  
 Item 15. Enter total number of draft/final
copies to be delivered.
  
 Item 16. Use for
additional/clarifying information for Items 1 through 15. Examples are: Tailoring of documents cited in Item 4; Clarification of submittal dates in Items 12 and 13; Explanation of reproducible copies in item 14.; Desired medium
for delivery of the data item.
	  	 FOR THE
CONTRACTOR
  
 Item 17. Specify appropriate
price group from one of the following groups of effort in developing estimated prices for each data item listed on the DD Form 1423.
  

a. Group I. Definition - Data which is not otherwise essential to the contractor’s performance of the primary contracted
effort (production, development, testing, and administration) but which is required by DD Form 1423.
  

Estimated Price - Costs to be included under Group I are those applicable to preparing and assembling the data item in
conformance with Government requirements, and the administration and other expenses related to reproducing and delivering such data items to the Government.
  

b. Group II. Definition - Data which is essential to the performance of the primary contracted effort but the contractor is
required to perform additional work to conform to Government requirements with regard to depth of content, format, frequency of submittal, preparation, control, or quality of the data item.

 
 Estimated Price - Costs to be included under Group II are
those incurred over and above the cost of the essential data item without conforming to Government requirements, and the administrative and other expenses related to reproducing and delivering such data item to the Government.

 
 c. Group III. Definition - Data which the contractor must
develop for his internal use in performance of the primary contracted effort and does not require any substantial change to conform to Government requirements with regard to depth of content, format, frequency of submittal, preparation, control, and
quality of the data item.
  
 Estimated Price - Costs to
be included under Group III are the administrative and other expenses related to reproducing and delivering such data item to the Government.
  

d. Group IV. Definition - Data which is developed by the contractor as part of his normal operating procedures and his effort in
supplying these data to the Government is minimal.
  

Estimated Price – Group IV items should normally be shown on the DD Form 1423 at no cost.

 
 Item 18. For each data item, enter an amount equal to that portion of
the total price which is estimated to be attributable to the production or development for the Government of that item of data. These estimated data prices shall be developed only from those costs which will be incurred as a direct result of the
requirement to supply the data, over and above those costs which would otherwise be incurred in performance of the contract if no data were required. The estimated data prices shall not include any amount for rights in data. The Government’s
right to use the data shall be governed by the pertinent provisions of the contract.
  

 DD FORM 1423-2 (BACK), AUG 96 

[†††] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.2

 EXHIBIT 10.2 
 SAREPTA THERAPEUTICS, INC. 
 2011 EQUITY INCENTIVE PLAN 

STOCK APPRECIATION RIGHT AWARD AGREEMENT (STOCK SETTLED) 
 Unless otherwise defined herein or in the Agreement, the terms defined in the AVI BioPharma, Inc. 2011 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock
Appreciation Right Award Agreement (the “Agreement”). 
 NOTICE OF STOCK APPRECIATION RIGHT 

 

			
	Participant Name:	  	                             
                               
		
	Address:	  	                             
                               
		
		  	                             
                               

 The participant listed above (“Participant”) has been granted a stock appreciation right (the
“SAR”) by Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., (the “Company”) relating to the aggregate number of shares of the Company’s Common Stock (“Stock”), set forth below, to be settled in
Common Stock upon exercise, subject to the terms and conditions of the Plan and this Agreement as follows: 
  

			
	Grant Number:	  	                             
                               
		
	Grant Date:	  	                             
                               
		
	Exercise Price per Share:	  	                             
                               
		
	Number of Shares of Stock relating to SAR:	  	                             
                               
		
	Total Exercise Price:	  	                             
                               
		
	Term/Expiration Date:	  	                             
                               
		
	Vesting Schedule:	  	 Subject to any acceleration provisions contained in the Plan or set forth below, this SAR may be exercise, in whole or in part, in
accordance with the following schedule:
  
 [Twenty five percent (25%) of the
shares of Stock subject to the SAR will vest and become exercisable on the one (1) year anniversary of the Vesting Commencement Date noted above, and 1/48th of the total number of shares of Stock subject to the SAR will vest and become exercisable
in equal monthly installments thereafter, such that one hundred percent (100%) of the shares of Stock subject to the SAR will be fully vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date noted above, subject to Participant remaining a Service Provider through
each such vesting date.

			
	Termination Period:	  	This SAR will be exercisable for [three (3)] months after Participant ceases to be a Service Provider, unless such Service Provider’s termination occurs by reason of
Participant’s death or Disability, in which case this SAR will be exercisable for [twelve (12)] months after Participant ceases to be a Service Provider. Notwithstanding the foregoing, in no event may this SAR be exercised after the
Term/Expiration Date as provided above and may be subject to earlier termination as provided in Section 15 of the Plan.

 By Participant’s signature and the signature of the Company’s representative below, Participant
and the Company agree that this SAR is awarded under and governed by the terms and conditions of the Plan and this Agreement, including the Terms and Conditions of Stock Appreciation Right Award, attached hereto as Exhibit A, all of which are
made a part of this document. Participant has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of the Plan and
Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions relating to the Plan and Agreement. Participant further agrees to notify the Company upon any
change in the residence address indicated below. 
  

									
	PARTICIPANT	 		 	SAREPTA THERAPEUTICS, INC.
			
	  
	 		 	  

	Signature	 		 		 	By	 	
			
	  
	 		 	  

	Print Name	 		 		 	Title	 	
					
	Address:	 		 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

 EXHIBIT A 
 TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHT AWARD 
 1. Grant of
Stock Appreciation Right. In consideration of Participant’s past and/or continued employment with or service to the Company or a Subsidiary and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant
Notice (the “Grant Date”), Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc. (the “Company”), hereby irrevocably grants to Participant a stock appreciation right (the “SAR”) under the AVI BioPharma, Inc.
2011 Equity Incentive Plan (the “Plan”) relating to the aggregate number of shares of the Company’s Common Stock (“Stock”), indicated in the Notice of Stock Appreciation Right (the “Grant Notice”), to be settled in
shares of Common Stock upon exercise, upon the terms and conditions set forth in the Plan and this Agreement. 
 2. Vesting
Schedule. Except as otherwise provided herein, the SAR shall become vested and exercisable with respect to such number of shares of Stock relating to the SAR and at such times as are set forth in the Grant Notice. Shares of Stock relating to the
SAR scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in Participant in accordance with any of the provisions of this Agreement, unless Participant will have been continuously a Service Provider from the
Grant Date until the date such vesting occurs. 
 3. Duration of Exercisability. Any installments provided for in the
vesting schedule set forth in the Grant Notice are cumulative. Each such installment which becomes vested and exercisable pursuant to the vesting schedule set forth in the Grant Notice shall remain vested and exercisable until it becomes
unexercisable under the Termination Period provisions set forth in the Grant Notice. 
 4. Administrator Discretion. The
Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested SAR at any time, subject to the terms of the Plan. If so accelerated, such SAR will be considered as having vested as
of the date specified by the Administrator. 
 5. Exercise Price. The exercise price of the shares of Stock relating to
the SAR shall be as set forth in the Grant Notice, without commission or other charge; provided, however, that the exercise price per share of Stock relating to the SAR shall not be less than 100% of the Fair Market Value of a share of
Stock on the Grant Date. 
 6. Payment upon Exercise. Upon exercise of the SAR, or any portion thereof, the Company shall
issue to Participant whole shares of Stock with a Fair Market Value (determined as of the date on which the SAR is exercised) equal to the product of (a) the number of shares of Stock relating to the SAR with respect to which the SAR is
exercised, and (b) the excess, if any, of (i) the Fair Market Value per share of Stock (which generally is to be equal to the closing sales price of the Stock) upon the date of such exercise over (ii) the exercise price per share of
Stock relating to such SAR rounded down to the nearest whole share. The Stock issued under this Agreement may be issued in book or other electronic form and a certificate for the shares of Stock shall only be delivered to Participant upon
Participant’s request unless otherwise restricted. 

 7. Person Eligible to Exercise. During the lifetime of Participant, only Participant
may exercise the SAR or any portion thereof. After the death of Participant, any exercisable portion of the SAR may, prior to the time when the SAR becomes unexercisable under Sections 2 or 3 hereof, be exercised by Participant’s personal
representative or by any person empowered to do so under the deceased Participant’s will or under then applicable laws of descent and distribution. 
 8. Partial Exercise. Any exercisable portion of the SAR or the entire SAR, if then wholly exercisable, may be exercised in whole or in part at any time prior to the time when the SAR or portion
thereof becomes unexercisable under the Termination Period provision set forth in the Grant Notice. 
 9. Manner of
Exercise. This SAR is exercisable by delivery of an exercise notice, in the form attached as Exhibit B (the “Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine,
which will state the election to exercise the SAR, the number of shares of Stock in respect of which the SAR is being exercised, and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan.
The Exercise Notice will be completed by Participant and delivered to the Company. This SAR will be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the satisfaction of all withholding
obligations. In the event the SAR or portion thereof shall be exercised pursuant to Section 8 hereof by any person or persons other than Participant, appropriate proof of the right of such person or persons to exercise the SAR may be required
by the Administrator. 
 10. Withholding Taxes. Notwithstanding any contrary provision of this Agreement, no certificate
representing the Stock will be issued to Participant, unless and until satisfactory arrangements (as determined by the Administrator) will have been made by Participant with respect to the payment of income, employment and other taxes which the
Company determines must be withheld with respect to such Stock. The Administrator may determine to permit or require the satisfaction of withholding taxes incurred upon such exercise by any of the following, or a combination thereof, as determined
appropriate by the Administrator, in its sole discretion: 
 (a) cash; 

(b) check; 

(c) consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan;

 (d) surrender of other shares of Common Stock which have a Fair Market Value on the date of surrender equal to the aggregate
withholding taxes incurred upon exercise, provided that accepting such Shares, in the sole discretion of the Administrator, will not result in any adverse accounting consequences to the Company; or 

(e) in the sole discretion of the Administrator, through the surrender of shares of Common Stock then issuable upon exercise of the SARs
having a Fair Market Value on the date of exercise equal to the aggregate withholding taxes incurred upon such exercise, calculated using the minimum statutory withholding rates. 

  
 A-2

 If Participant fails to make satisfactory arrangements for the payment of any required tax withholding
obligations hereunder at the time of the SAR exercise, Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the Stock if such withholding amounts are not delivered at the time of exercise.

 11. Rights as Shareholder. Neither Participant nor any person claiming under or through Participant will have any of
the rights or privileges of a shareholder of the Company in respect of any Stock deliverable hereunder unless and until certificates representing such Stock will have been issued, recorded on the records of the Company or its transfer agents or
registrars, and delivered to Participant. After such issuance, recordation and delivery, Participant will have all the rights of a shareholder of the Company with respect to voting such Stock and receipt of dividends and distributions on such Stock.

 12. Consideration to the Company; No Guarantee of Continued Service. In consideration of the grant of the SAR by the
Company, Participant agrees to render faithful and efficient services to the Company or any Parent or Subsidiary. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE SAR PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS
A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THE SAR OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES
THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL,
AND WILL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR
WITHOUT CAUSE. 
 13. Address for Notices. Any notice to be given to the Company under the terms of this Agreement will
be addressed to the Company at Sarepta Therapeutics, Inc., 3450 Monte Villa Parkway, Suite 101, Bothell, WA 98021, or at such other address as the Company may hereafter designate in writing. 

14. SAR Not Transferable. This SAR may not be transferred in any manner otherwise than by will or by the laws of descent or
distribution and may be exercised during the lifetime of Participant only by Participant. 
 15. Binding Agreement.
Subject to the limitation on the transferability of this grant contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. 

16. Additional Conditions to Issuance of Stock. If at any time the Company will determine, in its discretion, that the listing,
registration or qualification of the Shares upon any securities exchange or under any state or federal law, or the consent or approval of any 

  
 A-3

 
governmental regulatory authority is necessary or desirable as a condition to the issuance of shares of Stock to Participant (or his or her estate), such issuance will not occur unless and until
such listing, registration, qualification, consent or approval will have been effected or obtained free of any conditions not acceptable to the Company. The Company will make all reasonable efforts to meet the requirements of any such state or
federal law or securities exchange and to obtain any such consent or approval of any such governmental authority. Assuming such compliance, for income tax purposes the shares of Stock issued upon exercise of the SAR will be considered transferred to
Participant on the date the SAR is exercised with respect to such shares of Stock. The Administrator shall have the right to require Participant to comply with any timing or other restrictions with respect to the settlement of any SAR pursuant to
this Agreement, including a window-period limitation, as may be imposed in the discretion of the Administrator. Any shares of Stock that may be distributed pursuant to this Agreement may consist, in whole or in part, of authorized and unissued
shares, treasury shares or shares purchased on the open market. 
 17. Plan Governs. This Agreement is subject to all
terms and provisions of the Plan. In the event of a conflict between one or more provisions of this Agreement and one or more provisions of the Plan, the provisions of the Plan will govern. Capitalized terms used and not defined in this Agreement
will have the meaning set forth in the Plan. 
 18. Administrator Authority. The Administrator will have the power to
interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination
of whether or not any shares of Stock subject to the SAR have vested). All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other
interested persons. No member of the Administrator will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Agreement. 

19. Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to the SAR awarded under
the Plan or future equity awards that may be awarded under the Plan by electronic means or request Participant’s consent to participate in the Plan by electronic means. Participant hereby consents to receive such documents by electronic
delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

20. Captions. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction
of this Agreement. 
 21. Agreement Severable. In the event that any provision in this Agreement will be held invalid or
unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Agreement. 

22. Modifications to the Agreement. This Agreement (including all exhibits) and the Plan constitute the entire understanding of
the parties on the subjects covered. Participant expressly warrants that he or she is not accepting this Agreement in reliance on any promises, 

  
 A-4

 
representations, or inducements other than those contained herein. Modifications to this Agreement or the Plan can be made only in an express written contract executed by a duly authorized
officer of the Company. Notwithstanding anything to the contrary in the Plan or this Agreement, the Company reserves the right to revise this Agreement as it deems necessary or advisable, in its sole discretion and without the consent of
Participant, to comply with Section 409A or to otherwise avoid imposition of any additional tax or income recognition under Section 409A in connection to this SAR. 
 23. Amendment, Suspension or Termination of the Plan. By accepting this Award, Participant expressly warrants that he or she has received a SAR under the Plan, and has received, read and understood
a description of the Plan. Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time. 
 24. Governing Law. This Agreement will be governed by the laws of the State of Oregon, without giving effect to the conflict of law principles thereof. For purposes of litigating any dispute that
arises under this SAR or this Agreement, the parties hereby submit to and consent to the jurisdiction of the State of Oregon, and agree that such litigation will be conducted in the courts of the State of Oregon, or the federal courts for the United
States for the District of Oregon, and no other courts, where this SAR is made and/or to be performed. 
 25. Non-Waiver of
Rights. The Company’s failure to enforce at any time any of the versions of this Agreement or to require at any time performance by Participant of any of the provisions hereof shall in no way be construed to be a waiver of such provisions
or to affect either the validity of this Agreement, or any part hereof, or the right of Company thereafter to enforce each and every provision in accordance with the terms of this Agreement. 

26. Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if
Participant is subject to Section 16 of the Exchange Act, the Plan, the SAR and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any
amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable
exemptive rule. 
 27. Adjustments upon Specified Events. The Administrator may accelerate the vesting of the SAR in such
circumstances as it, in its sole discretion, may determine. In addition, upon the occurrence of certain events relating to the Stock contemplated by Section 15 of the Plan (including, without limitation, an extraordinary cash dividend on such
Stock), the Administrator shall make such adjustments the Administrator deems appropriate in the number of shares of Stock subject to the SAR and the exercise price of the SAR. Participant acknowledges that the SAR is subject to adjustment,
modification and termination in certain events as provided in this Agreement and Section 15 of the Plan. 

  
 A-5

 EXHIBIT B 
 SAREPTA THERAPEUTICS, INC. 
 2011 EQUITY INCENTIVE PLAN 

STOCK APPRECIATION RIGHT (STOCK SETTLED) EXERCISE NOTICE 
 Sarepta Therapeutics, Inc. 
 3450 Monte Villa Parkway, Suite 101 

Bothell, WA 98021 
 1.
Exercise of Stock Appreciation Right. Effective as of today,              , 20    , the undersigned (“Participant”) hereby elects to exercise the stock
appreciation right (the “SAR”) relating to                  shares (the “Shares”) of the Common Stock of Sarepta
Therapeutics, Inc., formerly known as AVI BioPharma, Inc., (the “Company”) under and pursuant to the AVI BioPharma, Inc. 2011 Equity Incentive Plan (the “Plan”) and the Stock Appreciation Right Award
Agreement dated August 23, 2012 (the “Agreement”). The exercise price for the Shares will be $        , as required by the Agreement. Capitalized terms used herein without
definition shall have the meanings given in the Plan and, if not defined in the Plan, the Agreement. 
 1. Delivery of
Payment. Participant herewith delivers to the Company any required tax withholding to be paid in connection with the exercise of the SAR. 
 2. Representations of Participant. Participant acknowledges that Participant has received, read and understood the Plan and the Agreement. Participant agrees to abide by and be bound by their terms
and conditions. 
 3. Rights as Shareholder. Until the issuance (as evidenced by the appropriate entry on the books of
the Company or of a duly authorized transfer agent of the Company) of the Stock, no right to vote or receive dividends or any other rights as a shareholder will exist with respect to the shares of Stock issued upon exercise of the SAR,
notwithstanding the exercise of the SAR. The shares of Stock so acquired will be issued to Participant as soon as practicable after exercise of the SAR. No adjustment will be made for a dividend or other right for which the record date is prior to
the date of issuance, except as provided in Section 15 of the Plan. 
 4. Tax Consultation. Participant understands
that Participant may suffer adverse tax consequences as a result of Participant’s exercise of the SAR or the disposition of any shares of Stock issued upon exercise of the SAR. Participant represents that Participant has consulted with any tax
consultants Participant deems advisable in connection with the exercise of the SAR or the disposition of such shares of Stock and that Participant is not relying on the Company for any tax advice. 

5. Entire Agreement; Governing Law. The Plan and the Agreement are incorporated herein by reference. This Exercise Notice, the
Plan, the Agreement and the Grant Notice constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter

 
hereof, and may not be modified adversely to Participant’s interest except by means of a writing signed by the Company and Participant. This Exercise Notice is governed by the internal
substantive laws, but not the choice of law rules, of the Commonwealth of Massachusetts. 
  

									
	 ACCEPTED BY:

SAREPTA THERAPEUTICS, INC.
	 		 	 SUBMITTED BY:
 PARTICIPANT

					
	By:	 	  
	 		 	By:	 	  

	Print Name:	 	  
	 		 	Print Name:	 	  

	Title:	 	  
	 		 		 	
		 		 		 	Address:	 	
		 		 		 	  

		 		 		 	  

	  
	 		 		 	
	Date Received	 		 		 	

  
 B-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]